Alcon Laboratories, Inc.

Alcon, Inc.

University of North Texas

Alcon Research, Ltd.

Arrowhead Pharmaceuticals, Inc.

Novartis Ag

Alcon Manufacturing, Ltd.

Arrowhead Research Corporation

Other

University of Iowa Research Foundation

Alcon Universal Ltd.

Abbot F Clark

Jon E Chatterton

Wan-Heng Wang

Loretta Graves McNatt

Martin B Wax

Raymond E Conrow

Robert J Wordinger

Iok-Hou Pang

David P Bingaman

Adrian M Timmers

Edwin M Stone

Allan R Shepard

John Fingert

Mark R Hellberg

Peter G Klimko

Billie M York

Yoseph Yaacobi

David Allen Marsh

Aaron L Southren

Debra L Fleenor

Peggy Elizabeth Hellberg

Nasreen Jacobson

Debra L Shade

Craig B Struble

David C Dahlin

Tasneem Putliwala Sharma

Colleen Mary McDowell

Husain Lohawala

Loretta Mcnatt

The present disclosure relates to devices, systems, and methods for modeling ocular translaminar pressure gradients ex vivo. A first fluid pressure level can be applied to a first side of a wall of donor eye cup (e.g., a posterior human eye cup) to simulate intracranial pressure (ICP), for example around the optical nerve head (ONH), and a second fluid pressure level can be applied to a second side of the wall of the donor eye cup to simulate intraocular pressure (IOP). These devices, systems, and methods are unique in that they allow ex vivo modeling of dynamic changes in translaminar pressure gradients.

Devices, systems, and methods for modeling ocular translaminar pressure gradients

The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.

Transferrin/transferrin receptor-mediated siRNA delivery

RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.

RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

RNA interference is provided for inhibition of tumor necrosis factor &#x3b1; (TNF&#x3b1;) by silencing TNF&#x3b1; cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF&#x3b1; converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF&#x3b1; targets, in particular, is useful for treating patients having a TNF&#x3b1;-related condition or at risk of developing a TNF&#x3b1;-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.

RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis

RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis

RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

RNA interference is provided for inhibition of tumor necrosis factor &#x3b1; (TNF&#x3b1;) by silencing TNF&#x3b1; cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF&#x3b1; converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF&#x3b1; targets, in particular, is useful for treating patients having a TNF&#x3b1;-related condition or at risk of developing a TNF&#x3b1;-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.

RNAi-related inhibition of TNF&#x3b1; signaling pathway for treatment of glaucoma

RNAi-related inhibition of TNF&#x3b1; signaling pathway for treatment of ocular angiogenesis

The present invention provides methods and kits for diagnosing and treating glaucoma.

Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma

Growing community of inventors

Arlington, TX, United States of America

Abbot F Clark